Lidolog Kit, 2% recall — Asclemed Usa Inc. (Class III)
Asclemed Usa Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Lidolog Kit, 2% — a Class III recall, initiated 2026-07-15 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0713-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan”. From the product description, the form is injection, the strengths given are 2% and 2mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 76420-760-01. Distribution is recorded as “Within U.S. - Tennessee”, with the recalling firm on record in CA, United States. It is the only recall number the FDA has filed under event ID 99408. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0713-2026 |
|---|---|
| FDA event ID | 99408 |
| Classification | Class III (least serious regulatory tier) |
| Status | Ongoing |
| Recalling firm | Asclemed Usa Inc. |
| Recall initiated | 2026-07-15 |
| Reported by FDA | 2026-07-29 |
| Report lag | 14 days from initiation to report |
| Distribution | Within U.S. - Tennessee |
| Firm location on record | CA, United States |
| Product description (source) | Lidolog Kit, Kit Contains: Lidocaine HCl Injection, USP, 2% (2mL) vial, 1 Dose, Single use Only, Rx Only, Distributed by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC: 76420-760-01. |
Reason reported by FDA
Labeling: Not Elsewhere Classified: The label wrap covers the barcode, making it hard to scan
15 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 27-word product description above; each is a literal substring of it.
| Product named | Lidolog Kit |
|---|---|
| Form | Injection · Kit |
| Strength | 2% · 2mL |
| NDC | 76420-760-01 |
| Marketing category | Rx only |
| Distributed by | Enovachem Pharmaceuticals, Torrance |
Other indexed recalls from Asclemed Usa Inc.
4 indexed records name Asclemed Usa Inc. as the recalling firm, across 3 FDA events, reported 2026-06-10 to 2026-07-29. A coverage-limited activity count over the ingested window, not a quality rating.
| Recall record | Recall number | FDA tier | Strength / form | Reported |
|---|---|---|---|---|
| Accucaine, 1% | D-0658-2026 | Class II | 1% · Injection | 2026-07-08 |
| Lidocaine HCl Injection USP, 1% | D-0659-2026 | Class II | 1% · Injection | 2026-07-08 |
| Duloxetine DR Capsules, 30 mg | D-0555-2026 | Class II | 30 mg · Capsules | 2026-06-10 |
Reported in the same month (2026-07)
111 enforcement reports carry a report date in 2026-07; these 4 are the Class III ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Dabigatran etexilate Capsules, 110 mg | D-0735-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
| Dabigatran etexilate Capsules, 150 mg | D-0736-2026 | Ascend Laboratories, LLC | Class III | 2026-07-29 |
| Fexofenadine Hydrochloride Tablets, 180 mg | D-0654-2026 | Sun Pharmaceutical Industries Inc | Class III | 2026-07-08 |
| hydrOXYzine Hydrochloride Oral Solution, 10 mg/5 mL | D-0619-2026 | Ani Pharmaceuticals, Inc. | Class III | 2026-07-01 |
Nearest Class III recalls by date
25 of 250 indexed records share the Class III tier; the 9 nearest to 2026-07-29 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Dabigatran Etexilate Capsules, 150 mg | D-0737-2026 | Ascend Laboratories, LLC | 150 mg · Capsules | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0738-2026 | Ascend Laboratories, LLC | 75 mg · Capsules | 2026-08-05 |
| Dabigatran Etexilate Capsules, 75 mg | D-0739-2026 | Ascend Laboratories, LLC | 75 mg · Capsules | 2026-08-05 |
| Total Parental Nutrition - Pediatric PN Patient-Specific TPN Bag, 416.8 mL | D-0740-2026 | Central Admixture Pharmacy Services Inc | 416.8 mL · Injection | 2026-08-12 |
| Focalin XR (dexmethylphenidate HCl) 5 mg | D-0608-2026 | Sandoz Inc | 5 mg · Extended-Release Capsules | 2026-06-24 |
| Epinephrine Injection, 1mg/mL | D-0581-2026 | Fresenius Kabi Usa, LLC | 1mg/mL · Injection | 2026-06-17 |
| Primidone Tablets, 50 mg | D-0585-2026 | Amneal Pharmaceuticals, LLC | 50 mg · Tablets | 2026-06-17 |
| Lidocaine HCl Injection, 2% | D-0552-2026 | Eugia US LLC | 2% · Injection | 2026-06-10 |
| Nicotine Transdermal System Patch, 14 mg | D-0550-2026 | Aveva Drug Delivery Systems, Inc. | 14 mg · Transdermal System | 2026-06-03 |
Reading this record
Class III is the FDA's own severity tier for the recall action — 25 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 76420-760-01 at the FDA source to confirm it is covered.
Namespace context: the Class III index (25 records) and the recall hub (250 records, 118 FDA events); Asclemed Usa Inc. (4 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0713-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0713-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-07-29
- Ingested
- 2026-08-22
- Record hash
64ddb5918a31b1ea
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.